Correlation between serum butyrylcholinesterase activity and serum lipid concentrations in rats treated with different antagonists of the adrenergic system

Periodicum Biologorum

Volumn 110, Issue 1, 2008, Pages 57-62

  Krnić, Žarka ^a,b   Tiljak, Mirjana Kujundžić ^c   Topić, Renata Zrinski ^d   Bradamante, Vlasta ^c  

^a PLIVA Research Institute Ltd   (Croatia)

^b Regulatory Affairs Sector   (Croatia)

^c UNIVERSITY OF ZAGREB   (Croatia)

^d SREBRNJAK CHILDREN S HOSPITAL   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; BUTYRYLTHIOCHOLINE; CHOLESTEROL; CHOLINESTERASE; DOXAZOSIN; GUANETHIDINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; OXPRENOLOL; TRIACYLGLYCEROL;

ADRENERGIC RECEPTOR BLOCKING; ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; COLORIMETRY; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DRUG EFFECT; ENZYME ACTIVITY; FISCHER 344 RAT; KINETICS; KRUSKAL WALLIS TEST; LIPID METABOLISM; MALE; NONHUMAN; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

RATTUS;

EID: 42549091936     PISSN: 00315362     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. SILVER A 1974 Pseudocholinesterases. In: The biology of cholinesterases. North-Holland Publishing Company, Amsterdam, p 411-449
2. HOFFMAN W E, WILSON B W, SOLTER P F 1999 Cholinesterases. In: Loeb W F, Quimby F W (ed) The clinical chemistry of laboratory animals, 2nd ed. Taylor & Francis, Philadelphia, p 430-440
3. KUTTY K M 1980 Review. Biological function of cholinesterase. Clin Biochem 13(6): 239-243
4. WHITTAKER M 1986 Cholinesterase in clinical medicine In: Cholinesterase. Karger, Basel, p 65-85
5. KALOW W 1952 Hydrolysis of local anesthetics by human serum cholinesterase. J Pharmacol Exp Ther 104: 122-134
6. CLITHEROW J W, MITCHARD M, HARPER N J 1963 The possible biological function of pseudocholinesterase. Nature 199: 1000-1001
7. BALLANTYNE B 1968 Histochemical and biochemical aspects of cholinesterase activity of adipose tissue. Arch Int Pharmacodyn 173(2): 343-349
8. BALLANTYNE B, BUNCH G A 1967 Esterase histochemistry in sebaceous glands. Dermatologica 134: 51-59
9. ANNAPURNA, V, SENCIALL I, DAVIS A J, KUTTY K M 1991 Relationship between serum pseudocholinesterase and triglycerides in experimentally induced diabetes mellitus in rats. Diabetologia 34: 320-324
10. KUTTY K M, HUANG S N, KEAN K T 1981 Pseudocholinesterase in obesity: Hypercaloric diet induced changes in experimental obese mice. Experientia 37: 1141-1142
11. KUTTY K M, PAYNE R H 1994 Serum pseudocholinesterase and verv-low-density lipoprotein metabolism. J Clin Lab Anal 8: 247-250
12. KEAN K T, KUTTY K M, HUANG S N, JAIN R 1986 A study of pseudocholinesterase induction in experimental obesity. J Am Coll Nutr 5: 253-261
13. ABBOTT C A, MACKNESS M I, KUMAR S, OLUKOGA A O, GORDON C, ARROL S, BHATNAGAR D, BOULTON A J M, DURRINGTON P N 1993 Relationship between serum butyrylcholinesterase activity, hypertriglyceridaemia and insulin sensitivity in diabetes mellitus. Clinical Science 85: 77-81
14. RUSTEMEIJER C, SCHOUTEN J A, VOERMAN H J, BEYNEN A C, DONKER A J M, HEINE R J 2001 Is pseudocholinesterase activity related to markers of triacylglycerol synthesis in type II diabetes mellitus? Clinical Science 101: 29-35
15. CUCUIANU M, POPESCU T A, HARAGUS S T 1968 Pseudocholinesterase in obese and hyperlipemic subjects. Clin Chim Acta 22: 151-155
16. CUCUIANU M, POPESCU T A, OPINCARU A, HARAGUS S 1975 Serum pseudocholinesterase and ceruloplasmin in various types of hyperlipoproteinemia. Clin Chim Acta 59: 19-27
17. CHU M I, FONTAINE P, KUTTY K M, MURPHY D, REDHEENDRAN R 1978 Cholinesterase in serum and low density lipoprotein of hyperlipidemic patients. Clinica Chimica Acta 85: 55-59
18. GOTO Y 1984 Effects of alpha- and beta-blocker antihypertensive therapy on blood lipids. A multicenter trial. Am J Med: 72-78
19. FERRARA L A, MAROTTA T, RUBBA P, DE SIMONE B, LECCIA G, SORO S, MANCINI M 1986 Effects of alpha-adrenergic and beta-adrenergic receptor blockade on lipid metabolism. Am J Med 80 (Suppl 2A): 104-108
20. KASISKE B L, MA J Z, KALIL R S N, LOUIS T A 1995 Effects of antyhypertensive therapy on serum lipids. Ann Intern Med 122(2): 133-141
21. AMES R P 1986 The effects of antihypertensive drugs on serum lipids and lipoproteins II. Non-diuretic drugs. Drugs 32: 335-357
22. LEHTONEN A 1983 β-Blockade and plasma lipids. J Pharmacol 14 (Suppl II): 203-208
23. LEHTONEN A, MARNIEMI J 1984 Effect of atenolol on plasma HDL cholesterol subfractions. Atherosclerosis 51: 335-338
24. LITHELL H 1993 Hypertension and hyerlipidemia. AJH 6: 303S-308S
25. LEREN P 1984 Effect of alpha- and beta-blocker therapy on blood lipids: European experience. Am J Med: 67-71
26. LEVY D, WALMSLEY P, LEVENSTEIN M 1996 Principal results of the Hypertension and Lipid Trial (HALT): A multicenter study of doxazosin in patients with hypertension. Am Heart J 131(5): 966-973
27. LOWENSTEIN J, NEUSY A-J 1984 Effects of prazosin and propranolol on serum lipids in patients with essential hypertension. Am J Med: 79-84
28. RABKIN S W 1993 Mechanisms of action of adrenergic receptor blockers on lipids during antihypertensive drug treatment. J Clin Pharmacol 33: 286-291
29. LANGIN D 2006 Adipose tissue lipolysis as a metabolic pathway to define pharmacological strategies against obesity and the metabolic syndrome. Pharmacol Res 53(6): 482-491
30. LAFONTAN M, BERLAN M 1993 Fat cell adrenergic receptors and the control of white and brown fat cell function. J Lipid Res 34: 1057-1091
31. TAVERNIER G, BARBE P, GALITZKY J, BERLAN M, CAPUT D, LAFONTAN M, LANGIN D 1996 Expression of β3-adrenoceptors with low lipolytic action in human subcutaneous white adipocytes. J Lipid Res 37: 87-97
32. NONOGAKI K 2000 New insights into sympathetic regulation of glucose and fat metabolism. Diabetologia 43: 533-549
33. 2-adrenoreceptors: The regulation of fat cell function and lipolysis. Endocrine Rev 16(6): 716-738
34. WHITTAKER M, WICKS R J, BRITTEN J J 1982 Studies on the inhibition by propranolol of some human erythrocyte membrane enzymes and plasma cholinesterase. Clinica Chimica Acta 119: 107-114
35. ALKONDON M, RAY A, SEN P 1986 Tissue cholinesterase inhibition by propranolol and related drugs. J Pharm Pharmacol 38: 848-850
36. KRNIĆ Ž, BRADAMANTE V 1997 Effects of oxprenolol treatment on pseudocholinesterase and lipids in rats. Arzneim-Forsch/Drug Res 47(II)8: 910-913
37. BRADAMANTE V, KRNIĆ Ž, ZRINSKI R, KONJEVODA P, REINER Ž 2006 Changes in butyrylcholinesterase activity and serum lipids after oxprenolol and glibenclamide treatments in non-diabetic rats. Arzneim-Forsch/Drug Res 56(2): 64-69
38. ANONYMOUS 1996 Guide for the care and use of laboratory animals. National Academy Press, Washington, p 1-125
39. EEC 1986 Directive for the protection of vertebrate animas used for experimental and other scientific purposes 86/609/EEC
40. KRNIĆ Ž 1994 Utjecaj kronične primjene oksprenolola na aktivnost kolinesteraze i koncentracije serumskih lipida u štakora. Magistarski rad. Medicinski fakultet Sveučilista u Zagrebu. Zagreb, Hrvatska [Engl. The influence of chronic oxprenolol treatment on pseudocholinesterase activity and concentration of serum lipids in rats. Master of Science Thesis].
41. LOEB W F 1999 The rat. In: Loeb W F, Quimby F W (ed)The clinical chemistry of laboratory animals, 2nd ed. Taylor & Francis, Philadelphia, p 33-48
42. RASOULI M, ZAHRAIE M 2006 Suppression of VLDL associated triacylglycerol secretion by both alpha- and beta-adrenoceptor agonists in isolated rat hepatocytes. Eur J Pharmacol 545(2-3): 109-114
43. GAAFAR K, SALAMA S, EL BATRAN S 1994 Studies on the glycemic and lipidemic effect of atenolol and propranolol in normal and diabetic rats. Arzneim-Forsch/Drug Res 44(4): 496-501
44. RABKIN S W, HUFF M W, NEWMAN C, SIM D, CARRUTHERS S G 1994 Lipids and lipoproteins during antihypertensive drug therapy Comparison of doxazosin and atenolol in a randomized, double-blind trial: The Alpha Beta Canada Study. Hypertension 24(2): 241-248
45. MAGARIAN E O, DIETZ A J 1987 Correlation of cholinesterase with serum lipids and lipoproteins. J Clin Pharmacol 27: 819-820